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ing	the	 levels	of	numerous	metabolic	 intermediates	and	products	 in	the	blood,	
allows	 a	 more	 detailed	 examination	 of	 metabolism	 dysfunctions.	 We	 aimed	 to	
identify	blood	metabolomic	markers	associated	with	weight	gain	in	psychiatric	
patients.	 Sixty-	two	 patients	 starting	 a	 treatment	 known	 to	 induce	 weight	 gain	
were	recruited.	Two	hundred	and	six	selected	metabolites	implicated	in	various	
pathways	were	analyzed	in	plasma,	at	baseline	and	after	1 month	of	treatment.	




nitines,	 carboxylic	 acids,	 catecholamines,	 nucleosides,	 pyridine,	 and	 tetrapyr-
role)	potentially	 involved	 in	metabolic	disruption	and	 inflammation	processes.	
The	predictive	potential	of	such	early	metabolite	changes	on	3 months	of	weight	
evolution	 was	 then	 explored	 using	 a	 linear	 mixed-	effects	 model.	 Of	 these	 19	
metabolites,	 short-	term	 modifications	 of	 kynurenine,	 hexanoylcarnitine,	 and	
biliverdin,	as	well	as	kynurenine/tryptophan	ratio	at	1 month,	were	associated	











depressants	 can	 induce	 important	 metabolic	 side	 effects,	
























the	 multiple	 mechanisms	 involved	 in	 drug-	induced	 WG	
and/or	worsening	of	other	metabolic	parameters.	 In	ad-
dition,	the	detection	of	early	alterations	of	such	biomark-
ers	 would	 allow	 one	 to	 predict	 metabolic	 outcomes	 and	
to	propose	individualization	of	treatment.	In	this	context,	
a	 WG	 higher	 than	 5%	 after	 1  month	 of	 treatment	 with	
weight-	inducing	psychotropic	drugs	was	demonstrated	to	
be	a	clinical	 sign	 to	consider	patients	as	being	at	higher	




Metabolomics	 is	 a	 powerful	 phenotyping	 approach	






Its	 exploration	 could	 permit	 identifying	 metabolic	 fin-
gerprints	 used	 as	 biomarkers,	 thus	 predicting	 a	 partic-
ular	phenotype.	When	possible,	pathway	exploration	of	
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Psychotropic	drugs	can	induce	weight	gain,	potentially	increasing	morbidity	and/
or	mortality	of	patients.
WHAT QUESTION DID THIS STUDY ADDRESS?
Could	the	use	of	metabolomics	permit	the	identification	of	early	blood	markers	
associated	with	weight	gain	in	treated	psychiatric	patients?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
It	identified	a	metabolomic	signature	related	to	psychotropic	drug	exposure.	Our	
results	 suggest	 an	 overall	 metabolic	 dysregulation	 after	 1  month	 of	 treatment,	
and	 a	 specific	 dysregulation	 that	 is	 associated	 with	 weight	 gain	 worsening	 at	
3 months.	Understanding	 the	biochemical	 significance	of	 those	dysregulations	
should	 provide	 further	 mechanistic	 comprehensions	 of	 pathways	 involved	 in	
metabolic	effects	of	psychotropic	drugs	and	possibly	also	in	therapeutic	response	
to	treatments.
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metabolites	 involved	 in	 this	 fingerprint	 could	 provide	
new	 insights	 into	 mechanisms	 that	 generate	 this	 phe-
notype.12,13	Recent	advances	in	mass	spectrometry	tech-
nology	 enable	 high	 sensitivity	 and	 broad	 coverage	 of	
the	 metabolome.14	 Moreover,	 high	 throughput	 analysis	
permits	rapid	performance	of	large-	scale	studies	of	hun-
dreds	of	metabolites,	 showing	an	undoubted	advantage	





Metabolomic	 fingerprints	 have	 been	 described	 for	 dif-
ferentiating	 several	 pathologies	 in	 the	 psychiatric	 pop-
ulation,	 providing	 potential	 biomarkers	 for	 facilitating	
diagnosis,	exploring	new	physiopathology	and	treatment	
hypotheses.15,16	 Studies	 focusing	 on	 variations	 of	 the	
metabolome	 after	 pharmacotherapy	 shed	 light	 on	 vari-
ous	 metabolic	 dysregulations.17	 Notably,	 disturbances	
in	 amino	 acid	 metabolism,	 antioxidant	 defense	 system,	
fatty	 acid	 biosynthesis,	 and/or	 phospholipid	 metabo-
lism	were	observed,	leading	to	global	energy	metabolism	
dysregulations	 after	 psychotropic	 drug	 treatment.18,19	
Interestingly,	metabolomic	profiles	after	treatment	were	
shown	 to	 differ	 depending	 on	 psychotropic	 drugs,	 in-
ducing	 different	 metabolic	 side	 effects	 during	 their	 ad-
ministration.20	 The	 predictive	 potential	 of	 a	 metabolic	
fingerprint	 profile	 before	 the	 instauration	 of	 the	 treat-
ment	for	early	personalized	intervention	is	more	sparsely	
studied.	Specifically,	regarding	the	WG	issue,	a	 link	be-
tween	 WG	 and	 increased	 baseline	 levels	 of	 triacylglyc-
erols	with	low	carbon	number	and	double-	bound	count	
was	 observed	 via	 lipidomic	 analysis.21	 More	 generally,	
the	list	of	reproducible	findings	is	limited,	reflecting	the	
complexity	 of	 mechanisms	 involved	 in	 WG	 during	 the	















after	 1  month	 of	 treatment	 on	 weight	 evolution	 after	
1  month	 and	 over	 3  months	 of	 treatment,	 respectively.	
Of	note,	due	to	the	targeted	nature	of	our	metabolomic	
analysis,	 mechanistic	 analysis	 via	 metabolic	 pathway	
analysis	was	not	performed.
METHODS
Study subjects and samples
An	 exploratory	 cohort	 of	 62	 patients	 was	 selected	 from	















monitoring,	 enabling	 control	 of	 compliance	 and	 phar-
macokinetic	 issues,	 including	 rapid	 metabolism	 and/or	
drug	interactions.	Baseline	and	1-	month	clinical	and	bio-
logical	data	were	recorded	during	a	medical	examination	
based	 on	 guidelines.23	 Only	 hospitalized	 patients	 were	
included	 in	 order	 to	 ascertain	 fasting	 conditions	 and	
rapid	 processing	 of	 samples	 after	 blood	 drawing	 (cen-
trifugation	at	4℃,	aliquoting	and	storage	at	−80℃	until	










The	 124	 plasma	 samples	 of	 the	 exploratory	 cohort	 were	





then	 reconstituted	 in	 100	 µl	 of	 a	 high	 aqueous	 solvent	
(water/10%	methanol)	before	injecting	5 µl	for	analysis.
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Based	on	published	protocol,24	a	targeted	metabolomic	
analysis	was	developed,	as	previously	described,25	allowing	
the	 detection	 of	 206	 metabolites	 (Table  S1).	 The	 detailed	
description	 of	 the	 experimental	 procedures	 can	 be	 found	
in	 the	 Supplementary	 Material.	 Data	 processing	 was	 per-
formed	 through	 MultiQuant	 software	 (version	 2.0,	 Sciex).	
















tified	 metabolomic	 signature,	 the	 link	 between	 baseline	
metabolite	levels	and	1-	month	weight	change	was	assessed	








adjusted	 for	 repeated	 measurements	 by	 including	 a	 ran-
dom	effect	for	each	individual.	Significant	metabolites	were	
considered	 to	 be	 predictive	 of	 intermediate-	term	 weight	
evolution.
Exploration of the kynurenine pathway
A	 validated	 liquid	 chromatography	 tandem	 mass	 spec-
trometry	 (LC-	MS/MS)	 method	 was	 applied	 to	 the	 172	
plasma	samples	of	 the	exploratory	and	confirmatory	co-
horts,	as	described	previously.30	This	method	allows	 the	
identification	 and	 quantification	 of	 tryptophan	 and	 14	
metabolites	 from	 the	 kynurenine	 pathway	 (KP)	 and	 is	
described	 in	 the	 Supplementary	 Material.	 Data	 process-
ing	 was	 performed	 through	 MassLynx	 software	 (version	
4.2,	 Waters).	 Concentration	 results	 were	 analyzed	 using	
MetaboAnalyst	3.026	and	R.28	A	significance	threshold	was	
set	at	a	p	value	of	0.05.	Adjustment	by	FDR	was	applied	
for	 the	 exploratory	 cohort,	 but	 not	 for	 the	 confirmation	
cohort.	 The	 same	 methodology	 as	 described	 previously	
was	used	first	to	identify	metabolites	from	the	KP	contrib-
uting	 to	 the	differentiation	of	patients	between	pre-	and	
post-	treatment,	 second,	 the	 link	 between	 baseline	 iden-









BMI,	 total	 cholesterol,	 including	 low-	density	 lipoprotein	
cholesterol,	 was	 significantly	 increased	 after	 1  month	 of	
treatment	in	the	discovery	cohort,	which	is	consistent	with	
metabolic	 side	 effects	 frequently	 observed	 under	 psycho-








Nineteen	 of	 206	 metabolites	 were	 retained	 after	 t-	test	
analyses,	highlighting	a	metabolomic	signature	that	dif-
ferentiates	patients	between	pre-	and	post-	treatment	in	
the	 exploratory	 cohort	 (Table  2).	 Multivariate	 partial	







acids	 (n  =  5),	 acylcarnitines	 (n  =  6),	 carboxylic	 acids	
(n  =  4),	 catecholamines	 (n  =  1),	 nucleosides	 (n  =  1),	
pyridine	 (n  =  1),	 and	 tetrapyrrole	 (n  =  1).	 Seven	 me-
tabolites,	 l-	alanine,	 kynurenine,	 6-	hydroxydopamine,	
N-	amidino-	l-	aspartate,	 pyridoxamine,	 propionylcar-
nitine,	 and	 creatine,	 were	 increased	 after	 1  month	 of	
treatment.	 The	 kynurenine/tryptophan	 ratio	 has	 pre-
viously	 been	 associated	 with	 the	 enzymatic	 activity	 of	
indoleamine-	2,3-	dioxygenase,	 a	 tryptophan-	degrading	
enzyme	 with	 enhanced	 activity	 under	 inflammation	
status.	In	this	context,	the	kynurenine/tryptophan	ratio	
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associated	 with	 WG	 over	 3  months	 (Figure  1).	 Thus,	
patients	 with	 a	 variation	 in	 kynurenine	 (p  =  0.046)	 or	
kynurenine/tryptophan	ratio	(p = 0.046),	and	in	biliver-
din	 (p  =  0.046)	 or	 hexanoylcarnitine	 (p  =  0.046),	 after	
1  month	 of	 treatment,	 higher	 and	 lower,	 respectively,	
than	 the	 median	 changes	 had	 significantly	 higher	 WG	
during	the	first	3 months	of	treatment.





ence	 of	 kynurenine	 in	 the	 metabolic	 signature,	 a	 quan-
titative	 analysis	 of	 metabolites	 of	 the	 KP	 was	 performed	




treatment.	 Linear	 regression	 analysis	 did	 not	 show	 any	









acid	 level	 (p  =  0.0007).	 In	 agreement	 with	 results	 from	





T A B L E  2 	 Analytes	whose	levels	were	significantly	modified	after	one	month	of	psychotropic	drug	use,	and	their	feature	classes
Analytes
Ionization 
mode HMDB ID t.stat pcorrected Feature class
3-	hydroxy-	3-	methylglutarate Negative HMDB00355 3.238 0.04 Carboxylic	acids
6-	hydroxydopamine Positive HMDB01537 −3.487 0.01 Catecholamines
Biliverdin Positive HMDB01008 3.953 0.004 Tetrapyrroles
Creatine Positive HMDB00064 −5.095 0.0005 Amino	acids
Decanoylcarnitine Positive HMDB00651 4.767 0.0009 Acylcarnitine
Deoxyuridine Positive HMDB00012 3.615 0.01 Pyrimidine	nucleosides
D-	galacturonic	acid Negative HMDB02545 4.450 0.0009 Carboxylic	acids
Hexanoylcarnitine Positive HMDB00705 4.119 0.003 Acylcarnitine
Hydroxypyruvate Negative HMDB01352 4.744 0.0005 Carboxylic	acids
Kynurenine Positive HMDB00684 −4.232 0.002 Amino	acids
Kynurenine/Tryptophan	ratio Positive —	 −4.058 0.003 Ratio	of	amino	acids
l-	alanine Positive HMDB00161 −3.192 0.03 Amino	acids
Lauroylcarnitine Positive HMDB02250 4.426 0.002 Acylcarnitine
Malonate Negative HMDB00691 5.604 <	0.0001 Carboxylic	acids
N-	Amidino-	l-	Aspartate Positive HMDB03157 −3.230 0.03 Amino	acids
Octanoylcarnitine Positive HMDB00791 4.666 0.0009 Acylcarnitine
Oleylcarnitine Positive HMDB05065 4.047 0.003 Acylcarnitine
Propionylcarnitine Positive HMDB00824 −3.075 0.03 Acylcarnitine
Pyridoxamine Positive HMDB01431 −3.125 0.03 Pyridines
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WG	over	3 months	uncovered	potential	 trends	 in	signif-
icance	 for	3-	hydroxy-	anthranilic	acid	 (p = 0.06)	and	 the	
kynurenine/tryptophan	ratio	(p = 0.07).
DISCUSSION
Considering	 psychotropic-	induced	 WG	 and	 the	 effects	 of	
WG	on	lifespan	and	quality	of	life,	there	is	a	need	to	identify	
markers	 that	 would	 help	 to	 predict	 substantial	 weight	 in-
crease	 during	 treatment.	 To	 our	 knowledge,	 the	 present	
study	 is	 the	 first	 to	 achieve	 a	 comprehensive	 metabolic	
profiling	 of	 patients	 starting	 treatment	 with	 WG-	inducing	
psychotropic	drugs.	With	each	patient	acting	as	his	or	her	
own	control,	a	 robust	metabolomic	 fingerprint,	 composed	
of	 19	 metabolites	 belonging	 to	 different	 chemical	 classes,	
was	shown	to	be	linked	to	1 month	of	treatment.	They	are	
involved	in	different	metabolic	pathways,	including	energy	
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metabolism,	oxidative	stress,	beta-	oxidation,	mitochondrial	
metabolism,	 amino	 acid	 metabolism,	 carbonyl	 stress,	 and	
pyrimidine	metabolism,	possibly	reflecting	new	insights	into	
metabolic	changes	after	1 month	of	psychotropic	treatment.
The	 link	 between	 identified	 metabolomic	 fingerprint	
and	 WG	 under	 treatment	 was	 studied.	 An	 ideal	 bio-




served	 during	 short-	term	 treatment	 (1  month)	 could	 be	
predictors	 of	 intermediate-	term	 (3  months)	 weight	 evo-
lution.	 Interestingly,	 increased	 kynurenine	 levels	 and	
kynurenine/tryptophan	 ratios,	 along	 with	 decreased	
biliverdin	and	hexanoylcarnitine	 levels	at	1 month	were	
significantly	associated	with	higher	WG	over	3 months	of	







catalyzed	 by	 tryptophan-	2,3-	dioxygenase	 and	 indoleamine-	




















Moreover,	 we	 underlined	 a	 supplementary	 variation	 in	 ky-






being	 possibly	 explained	 by	 the	 small	 sample	 size	 of	 this	
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cohort.	 The	 association	 of	 a	 dysregulated	 KP	 and	 obesity	
has	been	well-	established	both	through	metabolomics37	and	
specific	targeted	analyses.30	The	main	putative	mechanisms	
involve	 oxidative	 stress	 and	 chronic	 low-	grade	 inflamma-
tion	 with	 secretion	 of	 diverse	 pro-	inflammatory	 cytokines	
that	could	lead	to	increased	IDO	activity,	and,	consequently,	
a	 higher	 kynurenine/tryptophan	 ratio.	 As	 the	 KP	 interacts	
dynamically	 with	 the	 immune	 system,	 it	 is	 considered	 the	
crossroad	between	psychiatric	pathology,	drug	exposure,	and	




It	 was	 shown	 that	 benserazide	 attenuates	 the	 olanzapine-	
induced	excessive	WG	after	71 days	of	olanzapine	exposure,	




Our	 metabolomic	 analysis,	 which	 covers	 a	 list	 of	 10	
acylcarnitines,	 showed	 a	 significant	 increase	 in	 short	
chain	 propionylcarnitine	 and	 a	 decrease	 in	 intermediate	
as	well	 as	 long	chain	acylcarnitines,	namely	decanoylcar-
nitine,	 octanoylcarnitine,	 lauroylcarnitine,	 oleylcarnitine,	
and	 hexanoylcarnitine	 after	 1  month	 of	 treatment.	These	
changes	are	consistent	with	recently	published	studies.39–	43	
Acylcarnitines	 are	 organic	 compounds	 containing	 a	 fatty	
acid.	 They	 have	 a	 central	 role	 in	 transporting	 fatty	 acids	
across	 the	 mitochondrial	 inner	 membrane	 during	 beta-	
oxidation,	and	are	implicated	in	energy	production	and	cel-
lular	 homeostasis	 pathways.	 Their	 perturbations	 confirm	
mitochondrial	 dysfunction	 and	 disrupted	 fatty	 acid	 beta-	
oxidation	 during	 psychotropic	 treatment,42,43	 as	 well	 as	 a	
potential	dysfunction	of	enzymes	 involved	 in	synthesis	of	
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that	 short-	term	 decrease	 in	 biliverdin	 is	 associated	 with	
higher	WG	over	3 months	of	treatment.	Interestingly,	HO-	1	
expression	and	activity	have	been	shown	to	be	downregu-
lated	 in	obesity,	 leading	 to	excessive	oxidative	 stress	with	
impairment	 of	 the	 detoxification	 mechanism	 within	 adi-
pocytes,	 adipogenesis,	 and	 chronic	 inflammation	 state.46	
This	disruption	could	also	contribute	 to	 the	development	
of	other	metabolic	disturbances,	such	as	insulin	resistance	









Some	 limitations	 of	 the	 present	 study	 must	 be	 men-
tioned.	 Metabolome	 expression	 could	 be	 influenced	 by	
















in	 metabolite	 profiles	 between	 pre-	 and	 post-	treatment	 in	
this	 subgroup	 (data	 not	 shown).	 Different	 drugs	 could	 in-








included	 patients	 had	 current	 or	 previous	 treatment	 with	
WG-	inducing	psychotropic	drugs,	such	medications	possibly	














mic	 pattern	 caused	 by	 poor	 adherence	 or	 nonadherence	
to	 treatment).	 With	 this	 methodology,	 we	 showed	 that	






works,	 in	 order	 to	 connect	 multi-	omics	 measurement.49	
This	 integrative	 biology	 objective	 would	 provide	 better	
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